263 related articles for article (PubMed ID: 35072634)
1. Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study.
Hu J; Xing K; Zhang Y; Liu M; Wang Z
JMIR Med Inform; 2022 Apr; 10(4):e34548. PubMed ID: 35072634
[TBL] [Abstract][Full Text] [Related]
2. Intellectual Structure and Evolutionary Trends of Precision Medicine Research: Coword Analysis.
Lyu X; Hu J; Dong W; Xu X
JMIR Med Inform; 2020 Feb; 8(2):e11287. PubMed ID: 32014844
[TBL] [Abstract][Full Text] [Related]
3. Determining the Intellectual Structure and Academic Trends of Smart Home Health Care Research: Coword and Topic Analyses.
Kang HJ; Han J; Kwon GH
J Med Internet Res; 2021 Jan; 23(1):e19625. PubMed ID: 33475514
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
5. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
6. Global research trends and hotspots of fecal microbiota transplantation: A bibliometric and visualization study.
Wang M; Xie X; Zhao S; Han W; Zhang Y
Front Microbiol; 2022; 13():990800. PubMed ID: 36060783
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
8. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
9. Research hotspots and trends in nursing education from 2014 to 2020: A co-word analysis based on keywords.
Yang K; Wang L; Yang G; Jiang X
J Adv Nurs; 2022 Mar; 78(3):787-798. PubMed ID: 34514616
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies.
Makimoto G; Ohashi K; Maeda Y; Kiura K
Acta Med Okayama; 2020 Oct; 74(5):371-379. PubMed ID: 33106692
[TBL] [Abstract][Full Text] [Related]
11. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series.
Shin HJ; Kho BG; Kim MS; Park HY; Kim TO; Kim YI; Lim SC; Park CK; Kim YC; Choi YD; Oh IJ
Medicine (Baltimore); 2019 Mar; 98(9):e14699. PubMed ID: 30817606
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.
Vavalà T; Mariniello A; Novello S
Transl Cancer Res; 2019 Jan; 8(Suppl 1):S48-S54. PubMed ID: 35117063
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
14. Frequency, clinical features and differential response to therapy of concurrent
Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
[No Abstract] [Full Text] [Related]
15. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
16. Current perspectives for the treatment of chronic myeloid leukemia.
Aladağ E; Haznedaroğlu İC
Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
[TBL] [Abstract][Full Text] [Related]
17. Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis.
Zhang Y; Lu L; Zheng R
Front Pharmacol; 2023; 14():1140771. PubMed ID: 37214445
[No Abstract] [Full Text] [Related]
18. Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.
Li D; Song Z; Dong B; Song W; Cheng C; Zhang Y; Zhang W
J Clin Pharm Ther; 2022 Jan; 47(1):24-32. PubMed ID: 34309914
[TBL] [Abstract][Full Text] [Related]
19. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
20. Detecting the Interdisciplinary Nature and Topic Hotspots of Robotics in Surgery: Social Network Analysis and Bibliometric Study.
Shen L; Wang S; Dai W; Zhang Z
J Med Internet Res; 2019 Mar; 21(3):e12625. PubMed ID: 30912752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]